Pyxis Oncology (PYXS) Equity Ratio (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Equity Ratio data on file, last reported at 0.58 in Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.58, down 24.04% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.58 (down 24.04% YoY), and the FY2025 annual result was 0.58, down 24.04% from the prior year.
• Equity Ratio eased to 0.58 in Q4 2025 per PYXS's latest filing, from 0.65 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.93 in Q4 2021 and troughed at 0.51 in Q3 2021.
• A 5-year average of 0.71 and a median of 0.78 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio jumped 264.6% in 2022, then decreased 24.04% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.93 in 2021, then slipped by 18.47% to 0.76 in 2022, then dropped by 4.9% to 0.72 in 2023, then gained by 6.17% to 0.77 in 2024, then decreased by 24.04% to 0.58 in 2025.
• Business Quant data shows PYXS's Equity Ratio at 0.58 in Q4 2025, 0.65 in Q3 2025, and 0.71 in Q2 2025.